John Moriarty was Appointed as Executive Vice President and General Counsel at Portola-Pharmaceutical-Inc

Date of management change: March 12, 2018 

What Happened?

South San Francisco, -based Portola-Pharmaceutical-Inc Appointed John Moriarty as Executive Vice President and General Counsel


About the Company

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.


About the Person

John Moriarty is Executive Vice President and General Counsel at Portola. Previously, John held various legal leadership positions in the industry


Info Source



Other IT executives who recently changed jobs as well: Brannigan Amanda, Wright II John, Suko Todd, Schill Todd, Teahen Joshua, Hollowell Melvin, Muscovitch Zak, Herzog Ted, Doak Tera, Rampe Kevin, Karthikeyan Hrishi

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.